NCT03767270WithdrawnPhase 1
A Phase 1/2 Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered MRT5201 in Subjects With Ornithine Transcarbamylase Deficiency
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Withdrawn
- Sponsor
- Translate Bio, Inc.
- Primary Endpoint
- The incidence of treatment-emergent adverse events by treatment group
Study Overview
Brief Summary
This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single escalating doses of MRT5201 administered intravenously to subjects with OTC Deficiency (OTCD). This study will also evaluate the effect of a single dose of MRT5201 on metabolic markers of OTCD and ureagenesis; and determine an acceptable dosing interval of MRT5201.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have a documented diagnosis of OTCD.
- •Documented history of ≥1 symptomatic hyperammonemia event with ammonia ≥100 µmol/L
- •Subject's OTCD is stable as evidenced by meeting the following criteria:
- •Ammonia level <175 µmol/L during the Screening Period and at Baseline (Day -1)
- •No clinical symptoms of hyperammonemia during the Screening Period and at Baseline (Day -1)
- •If using nitrogen scavenger therapy, must be on a stable regimen for ≥28 days prior to signing informed consent
- •Subject has maintained a stable protein restricted diet (which may or may not include medical foods) and/or amino acid supplementation with no changes in calorie or protein goals and no changes in medical food and/or amino acid supplementation for ≥ 28 days prior to signing informed consent.
Exclusion Criteria
- •Any laboratory abnormality that may put the subject at increased risk by participating in this study.
- •Have any significant concurrent or past medical condition that would represent an unacceptable risk to the subject or might jeopardize the collection of high-quality data from the study. These include but are not limited to:
- •History of liver transplant, including hepatocyte therapy/transplant
- •History of liver disease
- •Positive viral serology test results for HIV type 1 or 2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody
- •Type I or Type II diabetes that is poorly controlled, in the opinion of the Investigator
- •Poorly controlled hypertension (defined as systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg)
- •Use of anticoagulants or platelet inhibitors, including but not limited to heparin and non-steroidal anti-inflammatory drugs (NSAIDS). Acetaminophen is permitted
- •Participation in previous clinical studies evaluating investigational OTCD therapies directed at expressing functional OTC protein (eg, OTC gene therapy studies, other mRNA replacement therapy) that has led to the presence of anti-OTC antibodies.
Arms & Interventions
MRT5201
Experimental
Single Ascending Low, Mid, and High doses of MRT5201
Intervention: MRT5201 (Biological)
Placebo
Placebo Comparator
Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
The incidence of treatment-emergent adverse events by treatment group
Time Frame: Week 24
The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) for each dosing cohort by treatment group, assessed by severity and relationship to study product.
Secondary Outcomes
- Effect of a single dose of MRT5201 on ureagenesis(Up to 1 month after single dose)
- Effect of single dose of MRT5201 on metabolic markers of OTCD(6 months after single dose)
- Pharmacokinetics parameters of MRT5201(1 month after single dose)
Investigators
Similar Trials
Completed
Phase 1
Safety Study of OA-235i in Subjects With Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNonalcoholic Fatty LiverNCT05680233Oasis Pharmaceuticals, LLC24
Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)Shock,HemorrhagicNCT01951560Dr. Hasan Alam59
Active, not recruiting
Phase 1
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsLeukemia, Myeloid, AcuteMyelodysplastic NeoplasmsNCT06618001Janssen Research & Development, LLC64
Completed
Phase 1
A Study of Single-dose ALXN2050 in Healthy AdultsHealthyNCT05047458Alexion Pharmaceuticals, Inc.28
Recruiting
Phase 1
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusDiabete Type 2NCT05268237Biolingus15